MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Pre-operative predominance of Tremor versus PIGD scores in drug OFF state predicts motor and non-motor outcomes of STN-DBS for Parkinson’s disease

    C. Nagireddy, K. Pillai, S. Joshua, A. Pnair, D. Panikar, M. Chacko, A. Kishore (Kochi, India)

    Objective: To test the predictive value of predominance of tremor versus PIGD scores on the motor and non-motor outcomes of bilateral STN DBS for Parkinson’s…
  • 2023 International Congress

    Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)

    L. Guedes, D. Hilt, M. Fonseca, I. Peixoto, H. Gama (Coronado, Portugal)

    Objective: To describe the safety profile and tolerability of BIA-28-6156 observed during phase 1 clinical trials. Background: BIA-28-6156 is a novel allosteric activator of beta-glucocerebrosidase…
  • 2023 International Congress

    Unveiling the Link between Stress-Related Disorders and Dysautonomic Symptoms in Parkinson’s Disease: A Cross-Sectional Study

    EJ. Acosta-Espinoza, IA. Ortiz-Marroquin, DI. Salinas-Leal, A. Salinas-Blancas, HM. Macias-Cruz, D. Martinez-Ramirez (Monterrey, Mexico)

    Objective: To explore the link between post-traumatic stress disorders and dysautonomic symptoms in Parkinson's disease. Background: Parkinson's disease is a complex condition that can lead…
  • 2023 International Congress

    Comparison of the MIBG uptake in the major salivary glands between progressive supranuclear palsy/corticobasal syndrome and Parkinson’s disease

    J. Ebina, M. Shibukawa, H. Morioka, J. Nagasawa, M. Yanagihashi, T. Hirayama, N. Ishii, S. Mizumura, S. Orimo, O. Kano (Tokyo, Japan)

    Objective: To compare the MIBG uptake in the major salivary gland between progressive supranuclear palsy/corticobasal syndrome (PSP/CBS) and Parkinson’s disease (PD). Background: 123I-metaiodobenzylguanidine (MIBG) myocardial…
  • 2023 International Congress

    Choroidal changes in Parkinson’s disease: A longitudinal follow up study

    P. Mailankody, R. Battu, PM. Pm, T. K, N. Kamble, R. Yadav, P. Pal (Bangalore, India)

    Objective: The objective of the study was to evaluate the longitudinal changes in the choroid layer of the eye in patients with Parkinson’s disease (PD).…
  • 2023 International Congress

    Effect of the COVID-19 pandemic on gait and other motor and non-motor symptoms in people with Parkinson’s disease

    A. Boddu, A. Glover, L. Pillai, T. Virmani (Little Rock, USA)

    Objective: To determine if the COVID-19 pandemic significantly impacted disease progression in people with Parkinson's disease (PwPD) Background: Few cross sectional and short-term longitudinal studies…
  • 2023 International Congress

    A strategic training framework for building research capacity in the Global Parkinson’s Genetics Program (GP2)

    MT. Periñan, S. Dey, C. Bale, M. Kuhl, H. Leonard, P. Lewis, S. Stott, MB. Makarious, A. Martinez-Carrasco, AJ. Noyce, S. Bandres-Ciga, GP2. Genetics Program (Seville, Spain)

    Objective: To promote and facilitate learning internationally with resources and expertise to serve the training needs of the Global Parkinson’s Genetics Program (GP2;www.gp2.org) and its…
  • 2023 International Congress

    Impact of endpoint selection on sample size calculations for disease-modifying clinical trials in Parkinson’s disease patients with GBA1 mutations

    M. Fonseca, G. Castilla-Fernández, J. Liu, J. Holenz, N. Mendonça, D. Simon (Porto, Portugal)

    Objective: To assess clinical trial sample size estimations under variable simulated scenarios for Parkinson’s disease (PD) patients with mutations in the β-glucocerebrosidade gene (GBA1). Background:…
  • 2023 International Congress

    The effect of subthalamic deep brain stimulation on response inhibition and voluntary action control depend on connectivity of the volume of activated tissue with the prefrontal cortex

    J. Waldthaler, A. Sperlich, C. Stüssel, K. Steidel, L. Timmermann, D. Pedrosa (Marburg, Germany)

    Objective: The effect of subthalamic deep brain stimulation on response inhibition and voluntary action control depend on connectivity of the volume of activated tissue with…
  • 2023 International Congress

    No laughing white matter: reduced integrity of the lateral nucleus basalis of Meynert pathway in Parkinson’s disease-related cognitive impairment

    R. Crockett, K. Wilkins, S. Aditham, H. Bronte-Stewart (Stanford, USA)

    Objective: Investigate differences in white matter integrity of the nucleus basalis of Meynert (NBM) tracts in Parkinson’s disease (PD) patients who develop mild cognitive impairment…
  • « Previous Page
  • 1
  • …
  • 184
  • 185
  • 186
  • 187
  • 188
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley